ClinicalTrials.gg
Not yet recruitingNCT05499702Updated Oct 28, 2026

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

A Phase 2 interventional study of Caloric Restriction and Hyperglycemic clamp in Type2diabetes, sponsored by Adrian Vella. Not yet recruiting at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Adrian Vella · Phase 2, Interventional, and Basic science

How we know

Updated Oct 28, 2026Now Not yet recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 149 under way, 2 of them phase 3. Insulin Resistance · United States.

Planned enrollment
659th of 936
20 · median 37
Started
2027
with 2 others
Phase 2
126 of 1,118
12 open now
Primary completion
2029-06
later than 128 of 146 live
Registered
971st of 1,118
by date

Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 659th largest by planned enrollment of the 936 interventional ones that give a count, is one of 3 that started in 2027, is one of 126 in phase 2, reaches primary completion later than 128 of the 146 other live ones, and was the 971st registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,118 studies in Insulin Resistance with a site in United States, or all of them as a file.
02

Study summary

Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.

Read the detailed description

T2DM and prediabetes are characterized by abnormal post-prandial suppression of glucagon, which contributes to postprandial hyperglycemia by increasing EGP. Although these effects are magnified by decreased and delayed insulin secretion, they are also apparent when insulin secretion is intact5. In rodents, altered glucagon signaling changes α-cell function and mass - an effect mediated by changes in circulating AA concentrations. Are the elevated concentrations of branched-chain AA and other AA metabolites in T2DM a cause or an effect of global α-cell dysfunction? Could altered glucagon signaling precipitate a vicious cycle resulting in T2DM?

This study will determine how caloric restriction alters hepatic glucagon action. Elevated fasting AA concentrations are associated with T2DM risk. In addition, hepatic steatosis has been associated with an impaired ability of glucagon to stimulate hepatic clearance of AAs. Prior studies have shown that caloric restriction lowers fasting glucose, EGP and glucagon. However, the effects on these parameters in the postprandial period are unclear. This experiment will examine to what degree the improvements produced by caloric restriction can be explained by improved hepatic glucagon action. Because caloric restriction decreases hepatic fat content the experiment will also determine if a reduction in hepatic fat content is associated with changes in glucagon's effects on hepatic AA, glucose, and lipid metabolism.

03

Conditions studied

  • Type2diabetes

Keywords

  • glucagon
  • insulin resistance
  • caloric restriction
  • hepatic steatosis
  • amino acid metabolism
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • We will recruit up to 20 weight-stable, subjects with type 2 diabetes
  • ≥ 28 Kg/M2
  • Diabetes is managed by diet alone or a combination of oral agents

Exclusion criteria

Exclusion Criteria:

  • History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
  • Active systemic illness or .
  • Symptomatic macrovascular or microvascular disease.
  • to MRI (e.g. metal implants, claustrophobia).
  • Hematocrit \< 35%
  • TSH \< 0.4 or > 5.5.
  • Consumption of > 2 alcohol drinks per day or > 14 per week or a positive AUDIT questionnaire.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Adults with type 2 diabetes

    20 subjects will be studied on one occasion, following 6 weeks of caloric restriction. They will be instructed to consume a diet of 900 kcal daily using meals derived from "Nutritional Guidelines after Bariatric Surgery". Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake. After this subjects will undergo a hyperglycemic clamp with 2 doses of glucagon infused.

    Behavioral: Caloric Restriction · Drug: Hyperglycemic clamp

Interventions

  • BehavioralCaloric Restriction

    Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from "Nutritional Guidelines after Bariatric Surgery". Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake

  • DrugHyperglycemic clamp

    Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism

06

What researchers measure

Primary outcomes

  1. Rate of leucine oxidation in response to rising glucagon concentrations

    tracer-determined amino acid catabolism

    Time frame: 240 minutes of study

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2027; primary completion for Jun 2029, 18 months later.

Of 49 non-industry phase 2 interventional studies under Insulin Resistance, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 65. This study's planned 18 months is below that.

Counting every sponsor, half of 59 studies reached it within 45 months; a quarter within 25 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Dec 2022 → Dec 2027, primary completion Jun 2027 → Jun 2029 and completion Dec 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 12, 2022
StartEst.
Dec 15, 2027was Dec 2022
Primary completionEst.
Jun 30, 2029was Jun 2027
CompletionEst.
Dec 31, 2029was Dec 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Not yet recruiting
changed Oct 28, 2026
Start date
Dec 15, 2022→Dec 15, 2027
Oct 28, 2026
Primary completion
Jun 30, 2027→Jun 30, 2029
Oct 28, 2026
Study completion
Dec 31, 2027→Dec 31, 2029
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Not yet recruiting
    Start date Dec 15, 2022→Dec 15, 2027
    Primary completion Jun 30, 2027→Jun 30, 2029
    Study completion Dec 31, 2027→Dec 31, 2029
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05499702
Lead sponsor
Adrian Vella
Responsible party
Adrian Vella (Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Aug 12, 2022
Start date
Dec 15, 2027 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Jeanette Laugen
Contact
Laugen.Jeanette@mayo.edu
5072558110
Adrian Vella
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion